| Subject: | Prescribing Information Changes for Dexedrine (dextroamphetamine sulfate) |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Thu, 24 Aug 2006 - 12:00 am |
| Audience: Psychiatrists, pediatricians, mental healthcare professionals, pharmacists and consumers
The FDA and GlaxoSmithKline have notified healthcare professionals of changes to the BOXED WARNING, WARNINGS and PRECAUTIONS sections of the prescribing information for Dexedrine (dextroamphetamine sulfate), approved for the treatment of Attention-Deficit Hyperactivity Disorder and narcolepsy.
The warnings describe reports of sudden death in association with CNS stimulant treatment at usual... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
REFERENCES:
External Links:
|
|
StayAlert! provides immediate notification of regulatory body legislation impacting the healthcare industry, helping you to meet regulatory compliance. Subscribers are notified of any new or revised regulations, provided with a summary of the regulation, followed by an implementation action plan and/or policy. Designed as an e-mail "push" method for rapid customer notification of healthcare compliance issues, paired with interpretative analysis and practical application, the StayAlert!® Virtual Compliance Administrator™ saves you time and money. The StayAlert! system was designed by healthcare professionals actively working in the healthcare environment, who were faced with attempting to competently provide quality care and services while "doing more with less". StayAlert! provides the answer to efficiently performing a variety of required job components from one centralized virtual location. StayAlert! improves data sharing and communications, thus reducing cost, broadening access and providing a system of documentation and follow-up. |
|
